Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 39%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is poised for growth with its key products in multiple therapeutic areas such as oncology, cardiovascular disease, infectious diseases, and immunology, led by its blockbuster drug Keytruda. The recent results from its Phase 2 CADENCE study for Winrevair in CpcPH due to HFpEF were impressive, with potential for a doubling of peak sales. The company also has a strong pipeline and a leading position in the animal health market. However, there are risks such as unsuccessful commercialization of new products, surprise negative trial results, and potential challenges to key patents that could impact the stock. Overall, we believe Merck is well-positioned for continued earnings growth, despite the LOE for Keytruda in the future.

Bears say

Merck & Co is set to see a decline in sales for Keytruda, its primary revenue driver, and investors may not appreciate the potential for growth through alternative product lines. The company is also facing risks in its clinical trials, which could result in costly failures. However, the recent positive data for Winrevair in treating pulmonary hypertension suggests potential for growth in this market, with a projected 70% chance of success. While Merck has already committed to a Phase 3 trial, any failures or delays could hinder its revenue growth in the long term.

Merck (MRK) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 39% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 18 analysts, Merck (MRK) has a Buy consensus rating as of May 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.